Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has received marketing approval from the ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a dive ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the ...

Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the ...

There are three different types of surgery: 1. Plaque excision/incision with grafting. The surgeon either cuts open the scar tissue to release the tightness, or cuts out the scar tissue and ...

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra achieved completely clear skin by week 24.